Live to 100 up

Soon to be more than 50 years in the position to replace the new body parts to those who will wear out, says a report in the Guardian on the health of seniors.

A recent report in The Lancet that are born more than half of all babies in the richest countries to live to 100. This means that older people need fitter and healthier if they want to enjoy the second part of her life.

Fortunately, there is a research project underway at the University of Leeds, by a greater unity of Bioengineering of the United Kingdom, the world leader in the research of artificial joint replacements performed. The work is based on the hip and knee done again designed to last 50 years instead of the usual 20th Seniors will be able to have a new cartilage in the knee and a kneecap and a new heart valves and patches on their veins. The breakthrough is wonderful that the body does not refuse to recognize the new parts of the immune system to them as members of the organization.

There was a concerted effort from industry, research councils and charities for research with the result that 50 million pounds of funding is now available. Scientists and engineers across the UK put their heads together to design and produce exciting new body parts.

Professor Eileen Ingham, deputy director of the Institute for Leeds' Medical and Biological Engineering, says: "None of us is getting younger. These therapies are available to help people, but only if we care about this world-class and to transform ideas into tangible products. The United Kingdom has to take a historic failure of innovations and good practice in, but we have some very good scientists. "

The professor said, developed new heart valves in order to last a lifetime and will not be rejected by the body. As she experiences a series of washes with buffers, detergents and XP enymes living cells and remnants of the cell membrane, "she said. Which accounts for any foreign DNA, which could for their release.

The rest of the scaffold is implanted by the surgeon and the patient's body, the rest of the work by saturating the cells with valves to prevent their work from the first day of the rejection.

The process has been successful in 40 patients, the first clinical trial in Brazil in 2005, knows no rejection of the new valve body.